Month: April 2021

Icelandair Group will publish its results for the first quarter of 2021 on Thursday 29 April 2021. An investor presentation will be webcasted in Icelandic in relation to the disclosure of the results at 8:30 am on 30 April 2021 at: http://www.icelandairgroup.is/investors/reports-and-presentations/webcast-next/. The presentation will be available after the meeting on the website: http://icelandairgroup.is  and under company news on http://www.nasdaqomxnordic.com/news/companynews

Boliga Gruppen A/S CVR nr. 25 07 87 80 (“Selskabet“) Fondsbørsmeddelelse nr. 12/2021 Bestyrelsen har d.d. modtaget vedhæftede meddelelse vedrørende en gruppe aktionærers fremsættelse af pligtmæssigt tilbud på Boliga Gruppen A/S. Aktionærerne består af Morten Tofte Jensen, Klaus Tofte Jensen, Ulrik Tofte Jensen, Peter Riggelsen Holding ApS og Daugaard Holding ApS. For yderligere information, kontakt venligst: Boliga Gruppen A/S Laust Farver, CEOTelefon: +45 28 40 49 88Mail: lf@boligagruppen.dk Vedhæftet filMeddelelse om fremsættelse af pligtmæssigt tilbud

Nasdaq CopenhagenLondon Stock ExchangeOther stakeholders Date        26.04.2021 Share buy-back programme – week 16 The share buy-back programme runs from and including 4 February 2021 up to and including 30 July 2021. During this period Ringkjøbing Landbobank will buy-back shares to a maximum market value of DKK 255 million under a share buy-back programme, see company announcement of 3 February 2021. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme:Date Number of shares Average purchase price (DKK) Total purchased under the programme (DKK)Total in accordance with the last announcement176,200603.91106,409,06019...

Nasdaq CopenhagenLondon Stock ExchangeØvrige interessenter Dato        26.04.2021 Aktietilbagekøbsprogram – uge 16 Aktietilbagekøbsprogrammet løber i perioden fra og med den 4. februar 2021 til og med den 30. juli 2021. I denne periode vil Ringkjøbing Landbobank tilbagekøbe aktier for en maksimal markedsværdi af 255 mio. kroner i et aktietilbagekøbsprogram, jf. selskabsmeddelelse af 3. februar 2021. Programmet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 og EU-Kommissionens delegerede forordning nr. 2016/1052 af 8. marts 2016, der tilsammen udgør ”Safe Harbour”-reguleringen. Følgende transaktioner er foretaget under programmet:Dato Antal aktier (stk.) Gennemsnitligkøbspris (kroner) Tilbagekøbt i altunder programmet (kroner)I alt i henhold til seneste meddelelse176.200603,91106.409.06019....

The Novian IT infrastructure and software services group had aggregated revenue of EUR 24.1 million in 2020, or 2.6% more than in 2019. The group’s aggregated EBITDA was EUR 1.8 million and compared to 2019 grew 14.9%. The Novian group’s net profit for the year, excluding nonrecurring and atypical losses in the value of investments, was EUR 0.6 million and increased 54.5% compared to 2019. Calculation of the results of the Novian group is based on the audited 2020 results of Novian Technologies, Novian Systems and Zissor. “Last year was a challenging time for organizations. Due to the restrictions of the pandemic, digitalization became even more relevant – from remote work to the ‘smart’ data, artificial intelligence and automation possibilities that enabled further business continuity and resilience. In that context, we are striving...

IT infrastruktūros paslaugų ir programavimo grupė „Novian“ per 2020 metus uždirbo 24,1 mln. eurų agreguotų pajamų arba 2,6 proc. daugiau nei per 2019 metus. Grupės agreguota EBITDA siekė 1,8 mln. eurų ir, lyginant su 2019 m., išaugo 14,9 proc. „Novian“ grupės grynasis pelnas, eliminavus vienkartinius ir netipinius investicijų nuvertėjimus,  šiuo laikotarpiu sudarė 0,6 mln. eurų ir atitinkamai padidėjo 54,5 proc. Apskaičiuojant „Novian“ grupės rezultatus, vertinami audituoti bendrovių „Novian Technologies“, „Novian Systems“ ir „Zissor“ 2020 m. rezultatai. „Praėjusieji metai organizacijoms ir verslui buvo iššūkių laikas – dėl pandemijos ribojimų skaitmenizacija tapo dar aktualesnė – pradedant nuotoliniu darbu ir baigiant „protingųjų“ duomenų, dirbtinio intelekto ir automatizacijos galimybėmis, leidusiomis išlaikyti veiklos tęstinumą ir...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. 26 April 2021, Hamilton, Bermuda Reference is made to the stock exchange release by Golden Ocean Group Limited (the “Company”) on 15 April 2021 regarding publication of a prospectus and commencement of a subsequent offering of up to 2,710,377 new ordinary shares in the Company at a subscription price of NOK 53.00 per share (the “Subsequent Offering“). The subscription period in the Subsequent Offering will expire today, 26 April 2021, at 16:30 hours (CEST). Correctly completed subscription...

Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trialRespiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.1–5 Nirsevimab is being investigated as a first-in-class single dose immunization to provide protection for all infants entering their first RSV season. Nirsevimab met its Phase 3 primary endpoint earlier than anticipated; regulatory submissions for all-infant indication to begin in 2022.PARIS – April 26, 2021 – Positive topline results from the Phase 3 MELODY trial showed nirsevimab reduced lower respiratory tract infections (LRTI) requiring medical attention (inpatient or outpatient) due to respiratory syncytial virus (RSV) in healthy preterm and term infants. RSV is the most common cause of LRTI and the leading cause of hospitalizations...